(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Principal Financial Group Inc. lifted its stake in shares of Biogen by 3.2% during the third quarter. Principal Financial ...
(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.
We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...
Venturi Wealth Management LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 73.8% in the 3rd quarter, ...
The company's CEO warned on Wednesday that U.S. revenue for Leqembi, which it developed in partnership with Eisai Inc., “continues to be below the expectations of our collaboration.” ...
INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback